Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
TSH is the most sensitive marker, and high TSH and low free T4 confirm primary hypothyroidism
But it also raises IGF-1, disrupts glucose metabolism, and can accelerate unwanted tissue growth
Human clinical evidence is insufficient to confirm therapeutic benefit
Most common adverse events at all doses: Nausea (3355%, dose-related) Vomiting (1335%) Decreased appetite (1528%) Constipation or diarrhea (1020%) Injection-site reaction (510%) Dose-related dysesthesia signal: The TRIUMPH-4 trial identified a dose-related dysesthesia (nerve-tingling, paresthesia) signal: This is the most-flagged trial-level safety signal for retatrutide and the reason community doses cluster at 2-4 mg/week well below where the dysesthesia signal becomes prominent
Neuroscience and Behavioral Physiology, 22 (4), 275-279
